Tag: Respiratory
PharmaSignal — Respiratory
AZ is three for three with COPD hope tozorakimab
Pharmaphorum
AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.
Pulmonary fibrosis drug developer Avalyn files IPO
Pharmaphorum
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic
BioSpace
Analysts are cautiously optimistic about an IPO rebound for biopharma.
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
BioSpace
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
BioPharma Dive
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.